Navigation Links
CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
Date:1/29/2009

tion of the risks.

Anticipated milestones for CR011-vcMMAE through June 2009 include:

  • Complete and report on the final Phase II results of CR011-vcMMAE in metastatic melanoma in the second quarter of 2009

  • Advance and report on the initial Phase II results of CR011-vcMMAE in breast cancer in the second quarter of 2009

CuraGen expects to use an average of $3.5 to $4.0 million of cash and investments per quarter in the first half of 2009 to fund operations and also expects to end the second quarter of 2009 with between $80 and $81 million of cash and investments.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the Company's revenue, expenses, depreciation, amortization, asset impairment charges, losses, income, and future cash and investment positions, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CuraGen Reports Third Quarter 2008 Financial Results
2. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
3. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
4. CuraGen to Present at the BIO CEO & Investor Conference
5. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
6. CuraGen Corporation Receives Notification from NASDAQ
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
9. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
10. CuraGen Appoints Clinical Oncologist as VP of Medical Development
11. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... new study by a team including scientists from the National ... films can have different properties depending on the method by ... is necessary to explore the best way of creating these ... to computer memory devices. Thin films spread atop a ...
... 3, 2012 PDL BioPharma, Inc. (PDL) (NASDAQ: ... ended March 31, 2012. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) ... increased five percent over the same period of 2011. Total ... compared to $83.3 million for the same period of 2011. ...
... VRNM ), a leading industrial biotechnology company focused on ... announced that it will release 2012 first quarter financial results ... with the release, the Company will host a conference call ... ET. The call may be accessed by dialing ...
Cached Biology Technology:Fabrication method can affect the use of block copolymer thin films 2PDL BioPharma Announces First Quarter 2012 Financial Results 2PDL BioPharma Announces First Quarter 2012 Financial Results 3PDL BioPharma Announces First Quarter 2012 Financial Results 4PDL BioPharma Announces First Quarter 2012 Financial Results 5Verenium Corporation To Announce First Quarter 2012 Financial Results 2
(Date:10/25/2014)... , Oct. 22, 2014 A recent ... analysis of the current and future genetic testing market. ... and types are covered in this report. On account ... trends; drivers; and existing strengths and challenges; forecast for ... market is likely to grow at a CAGR of ...
(Date:10/22/2014)... Oct. 20, 2014  Leading identity analyst firm Acuity ... of the world,s population will have a chip-based National ... Europe . Asia , with ... accounting for more than 60% of all National eID ... report  -- "The Global National eID Industry ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Whole-exome sequencing shows potential as diagnostic tool 2
... 2 October 2009] A derivative of cholesterol is necessary ... study from the Swedish medical university Karolinska Institutet. The ... Stem Cell , can help scientists to cultivate dopamine-producing ... led by Professor Ernest Arenas and demonstrates that the ...
... Center for Molecular Medicine (MDC) Berlin-Buch has been honored ... National Academy of Sciences Leopoldina and the Stifterverband fr ... GDR civil rights activist received the award for his ... The award was presented to him at the annual ...
... may be a source of green, renewable hydrocarbons that ... according to a team of researchers led by Iowa ... R. Hoppe Professor of Chemical Engineering, said some plants ... carbon and energy. And those hydrocarbons could be used ...
Cached Biology News:Professor Jens Reich first recipient of the Carl Friedrich von Weizsacker award 2Professor Jens Reich first recipient of the Carl Friedrich von Weizsacker award 3Iowa State researchers looking for catalyst that allows plants to produce hydrocarbons 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... analysis kit for 10 chips provides the ... analysis with the Experion automated electrophoresis system. ... 3 x 520 microliters Pro260 gel, 45 ... (10-260 kD), 400 microliters Pro260 sample buffer, ...
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
Biology Products: